Eintrag weiter verarbeiten
| author_facet |
Liu Liu |
|---|---|
| author |
Liu |
| spellingShingle |
Liu Vaccines A Comparison of Plasmid DNA and mRNA as Vaccine Technologies Pharmacology (medical) Infectious Diseases Drug Discovery Pharmacology Immunology |
| author_sort |
liu |
| spelling |
Liu 2076-393X MDPI AG Pharmacology (medical) Infectious Diseases Drug Discovery Pharmacology Immunology http://dx.doi.org/10.3390/vaccines7020037 <jats:p>This review provides a comparison of the theoretical issues and experimental findings for plasmid DNA and mRNA vaccine technologies. While both have been under development since the 1990s, in recent years, significant excitement has turned to mRNA despite the licensure of several veterinary DNA vaccines. Both have required efforts to increase their potency either via manipulating the plasmid DNA and the mRNA directly or through the addition of adjuvants or immunomodulators as well as delivery systems and formulations. The greater inherent inflammatory nature of the mRNA vaccines is discussed for both its potential immunological utility for vaccines and for the potential toxicity. The status of the clinical trials of mRNA vaccines is described along with a comparison to DNA vaccines, specifically the immunogenicity of both licensed veterinary DNA vaccines and select DNA vaccine candidates in human clinical trials.</jats:p> A Comparison of Plasmid DNA and mRNA as Vaccine Technologies Vaccines |
| doi_str_mv |
10.3390/vaccines7020037 |
| facet_avail |
Online Free |
| finc_class_facet |
Chemie und Pharmazie Medizin |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMzM5MC92YWNjaW5lczcwMjAwMzc |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMzM5MC92YWNjaW5lczcwMjAwMzc |
| institution |
DE-15 DE-Pl11 DE-Rs1 DE-105 DE-14 DE-Ch1 DE-L229 DE-D275 DE-Bn3 DE-Brt1 DE-Zwi2 DE-D161 DE-Gla1 DE-Zi4 |
| imprint |
MDPI AG, 2019 |
| imprint_str_mv |
MDPI AG, 2019 |
| issn |
2076-393X |
| issn_str_mv |
2076-393X |
| language |
English |
| mega_collection |
MDPI AG (CrossRef) |
| match_str |
2019acomparisonofplasmiddnaandmrnaasvaccinetechnologies |
| publishDateSort |
2019 |
| publisher |
MDPI AG |
| recordtype |
ai |
| record_format |
ai |
| series |
Vaccines |
| source_id |
49 |
| title |
A Comparison of Plasmid DNA and mRNA as Vaccine Technologies |
| title_unstemmed |
A Comparison of Plasmid DNA and mRNA as Vaccine Technologies |
| title_full |
A Comparison of Plasmid DNA and mRNA as Vaccine Technologies |
| title_fullStr |
A Comparison of Plasmid DNA and mRNA as Vaccine Technologies |
| title_full_unstemmed |
A Comparison of Plasmid DNA and mRNA as Vaccine Technologies |
| title_short |
A Comparison of Plasmid DNA and mRNA as Vaccine Technologies |
| title_sort |
a comparison of plasmid dna and mrna as vaccine technologies |
| topic |
Pharmacology (medical) Infectious Diseases Drug Discovery Pharmacology Immunology |
| url |
http://dx.doi.org/10.3390/vaccines7020037 |
| publishDate |
2019 |
| physical |
37 |
| description |
<jats:p>This review provides a comparison of the theoretical issues and experimental findings for plasmid DNA and mRNA vaccine technologies. While both have been under development since the 1990s, in recent years, significant excitement has turned to mRNA despite the licensure of several veterinary DNA vaccines. Both have required efforts to increase their potency either via manipulating the plasmid DNA and the mRNA directly or through the addition of adjuvants or immunomodulators as well as delivery systems and formulations. The greater inherent inflammatory nature of the mRNA vaccines is discussed for both its potential immunological utility for vaccines and for the potential toxicity. The status of the clinical trials of mRNA vaccines is described along with a comparison to DNA vaccines, specifically the immunogenicity of both licensed veterinary DNA vaccines and select DNA vaccine candidates in human clinical trials.</jats:p> |
| container_issue |
2 |
| container_start_page |
0 |
| container_title |
Vaccines |
| container_volume |
7 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792346304238583810 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T17:36:42.635Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=A+Comparison+of+Plasmid+DNA+and+mRNA+as+Vaccine+Technologies&rft.date=2019-04-24&genre=article&issn=2076-393X&volume=7&issue=2&pages=37&jtitle=Vaccines&atitle=A+Comparison+of+Plasmid+DNA+and+mRNA+as+Vaccine+Technologies&aulast=Liu&rft_id=info%3Adoi%2F10.3390%2Fvaccines7020037&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792346304238583810 |
| author | Liu |
| author_facet | Liu, Liu |
| author_sort | liu |
| container_issue | 2 |
| container_start_page | 0 |
| container_title | Vaccines |
| container_volume | 7 |
| description | <jats:p>This review provides a comparison of the theoretical issues and experimental findings for plasmid DNA and mRNA vaccine technologies. While both have been under development since the 1990s, in recent years, significant excitement has turned to mRNA despite the licensure of several veterinary DNA vaccines. Both have required efforts to increase their potency either via manipulating the plasmid DNA and the mRNA directly or through the addition of adjuvants or immunomodulators as well as delivery systems and formulations. The greater inherent inflammatory nature of the mRNA vaccines is discussed for both its potential immunological utility for vaccines and for the potential toxicity. The status of the clinical trials of mRNA vaccines is described along with a comparison to DNA vaccines, specifically the immunogenicity of both licensed veterinary DNA vaccines and select DNA vaccine candidates in human clinical trials.</jats:p> |
| doi_str_mv | 10.3390/vaccines7020037 |
| facet_avail | Online, Free |
| finc_class_facet | Chemie und Pharmazie, Medizin |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMzM5MC92YWNjaW5lczcwMjAwMzc |
| imprint | MDPI AG, 2019 |
| imprint_str_mv | MDPI AG, 2019 |
| institution | DE-15, DE-Pl11, DE-Rs1, DE-105, DE-14, DE-Ch1, DE-L229, DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161, DE-Gla1, DE-Zi4 |
| issn | 2076-393X |
| issn_str_mv | 2076-393X |
| language | English |
| last_indexed | 2024-03-01T17:36:42.635Z |
| match_str | 2019acomparisonofplasmiddnaandmrnaasvaccinetechnologies |
| mega_collection | MDPI AG (CrossRef) |
| physical | 37 |
| publishDate | 2019 |
| publishDateSort | 2019 |
| publisher | MDPI AG |
| record_format | ai |
| recordtype | ai |
| series | Vaccines |
| source_id | 49 |
| spelling | Liu 2076-393X MDPI AG Pharmacology (medical) Infectious Diseases Drug Discovery Pharmacology Immunology http://dx.doi.org/10.3390/vaccines7020037 <jats:p>This review provides a comparison of the theoretical issues and experimental findings for plasmid DNA and mRNA vaccine technologies. While both have been under development since the 1990s, in recent years, significant excitement has turned to mRNA despite the licensure of several veterinary DNA vaccines. Both have required efforts to increase their potency either via manipulating the plasmid DNA and the mRNA directly or through the addition of adjuvants or immunomodulators as well as delivery systems and formulations. The greater inherent inflammatory nature of the mRNA vaccines is discussed for both its potential immunological utility for vaccines and for the potential toxicity. The status of the clinical trials of mRNA vaccines is described along with a comparison to DNA vaccines, specifically the immunogenicity of both licensed veterinary DNA vaccines and select DNA vaccine candidates in human clinical trials.</jats:p> A Comparison of Plasmid DNA and mRNA as Vaccine Technologies Vaccines |
| spellingShingle | Liu, Vaccines, A Comparison of Plasmid DNA and mRNA as Vaccine Technologies, Pharmacology (medical), Infectious Diseases, Drug Discovery, Pharmacology, Immunology |
| title | A Comparison of Plasmid DNA and mRNA as Vaccine Technologies |
| title_full | A Comparison of Plasmid DNA and mRNA as Vaccine Technologies |
| title_fullStr | A Comparison of Plasmid DNA and mRNA as Vaccine Technologies |
| title_full_unstemmed | A Comparison of Plasmid DNA and mRNA as Vaccine Technologies |
| title_short | A Comparison of Plasmid DNA and mRNA as Vaccine Technologies |
| title_sort | a comparison of plasmid dna and mrna as vaccine technologies |
| title_unstemmed | A Comparison of Plasmid DNA and mRNA as Vaccine Technologies |
| topic | Pharmacology (medical), Infectious Diseases, Drug Discovery, Pharmacology, Immunology |
| url | http://dx.doi.org/10.3390/vaccines7020037 |